This week, six companies submitted applications to the Hong Kong Stock Exchange, half of them aiming for an “A+H” listing.

Mars Finance news, July 11: According to information disclosed by the Hong Kong Exchanges and Clearing Limited (HKEX), from July 6 to July 10, a total of 6 companies submitted listing prospectuses to HKEX. They are Shenzhen Chintianxia Technology Co., Ltd., Jiangsu Zhiyuan Pharmaceutical Co., Ltd., Mingyu Pharmaceutical Co., Ltd. - B, Shenzhen Bochu New Materials Co., Ltd., Guangzhou Founder Electronics Technology Co., Ltd., and Hubei Dinglong Holding Co., Ltd.

Among them, Bochu New Materials, ViewSonic shares, and Dinglong shares have all been listed on A-shares, and each holds a leading position in its respective sub-segment. As a provider of magnetic materials, Bochu New Materials, based on 2025 revenue, ranks first globally in the market for alloy soft magnetic powder cores with a market share of 27.1%, and ranks fifth globally in the AI-chip inductor market with a market share of 7.6%. ViewSonic shares, meanwhile, is making breakthroughs across the intelligent display sector: in the global shipment scale of LCD TV control boards, it ranks first. Its two major homegrown brands—Seewo Education interactive flat panels and MAXHUB conference flat panels—respectively hold the top spot in global market share for interactive flat panels and have won nine consecutive crowns in domestic conference flat panel sales. Dinglong shares started out with printing and photocopying consumables; today, its semiconductor materials business accounts for more than half, and it has risen to become China’s largest supplier of CMP polishing pads and OLED coating-type functional materials.

In addition, Zhiyuan Pharmaceutical and Mingyu Pharmaceutical are in different medical tracks. Zhiyuan Pharmaceutical focuses on dermatology for external use. With investments from Innovestment under Li Kaifu and Alibaba Health, it is expected to become the “No. 1 acne-removal stock.” From 2023 to 2025, revenue is projected to grow from 10.31 billion yuan to 13.24 billion yuan, with the overall gross margin remaining stable at 66%~72%. It has more than 30 candidate products in its R&D pipeline, and plans to launch 15~20 new products over the next three to five years. Mingyu Pharmaceutical focuses on the development of ADC antibody-drug conjugates and advanced immunotherapies. Its pipeline includes 11 candidate products in total. Its core products are currently aimed at solid tumors and thyroid eye disease, respectively. As of now, there are still no products that have achieved commercialized sales, and the company has accumulated net losses of over 1.4 billion yuan since its establishment.

Chintianxia’s main business is the research and development, design, and sales of code-based flash memory chips. The company previously filed for a ChiNext IPO in April 2022 and passed review in November of the same year. Later, due to large differences between its performance forecasts and actual results, it received a regulatory warning from the Shenzhen Stock Exchange, and in December 2023 it voluntarily withdrew its application. The latest financial data shows that in Q1 2026, the company’s revenue increased year over year by 77.4% to 224 million yuan, and its net profit reached 75.90 million yuan, which is equivalent to 278.8% of the company’s full-year net profit in 2025. (Ke Gu Bao news report)